Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Diabetic and Non-diabetic Human Leukocytic Responses to Different Capsule Types of Klebsiella pneumoniae Responsible for Causing Pyogenic Liver Abscess.
Lee IR, Sng E, Lee KO, Molton JS, Chan M, Kalimuddin S, Izharuddin E, Lye DC, Archuleta S, Gan YH. Lee IR, et al. Among authors: lee ko. Front Cell Infect Microbiol. 2017 Sep 7;7:401. doi: 10.3389/fcimb.2017.00401. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28936426 Free PMC article.
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY, Lee IR, Lim C, Teo J, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Ng LFP, Ren EC, Lin RTP, Wang LF, Renia L, Lye DC, Young BE. Poh XY, et al. Among authors: lee ir. Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2. Trials. 2022. PMID: 35710572 Free PMC article.
Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial.
Lee IR, Tong SYC, Davis JS, Paterson DL, Syed-Omar SF, Peck KR, Chung DR, Cooke GS, Libau EA, Rahman SBA, Gandhi MP, Shi L, Zheng S, Chaung J, Tan SY, Kalimuddin S, Archuleta S, Lye DC. Lee IR, et al. Trials. 2022 Jul 19;23(1):572. doi: 10.1186/s13063-022-06495-3. Trials. 2022. PMID: 35854360 Free PMC article.
Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).
Goh YS, Fong SW, Hor PX, Loh CY, Tay MZ, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Lee IR, Rao S, Chia PY; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L. Goh YS, et al. Among authors: lee ir. Int J Infect Dis. 2024 Sep;146:107147. doi: 10.1016/j.ijid.2024.107147. Epub 2024 Jun 28. Int J Infect Dis. 2024. PMID: 38945433 Free article.
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Poh XY, Lee IR, Tan CW, Chavatte JM, Fong SW, Goh YS, Rouers A, Wong N, Torres-Ruesta A, Mah SYY, Yeoh AYY, Gandhi M, Rahman N, Chin YQ, Lim JJ, Yoong TJK, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim DRX, Chia W, Renia L, Ren EC, Lin RTP, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: lee ir. EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12. EBioMedicine. 2024. PMID: 39137572 Free PMC article. Clinical Trial.
73 results